Search clinical trials for: Anlotinib hydrochloride capsule

Total 11236 results

Cancer Institute and Hospital, Chinese Academy...

Unknown

To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer

Lung Cancer
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Xianhai Mao
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection (ALTER-H006)

Hepatocellular Carcinoma | Adjuvant Therapy

China
Sun Yat-sen University

Unknown

Treating Locally Advanced Head and Neck Malignant Tumor With Anlotinib and Chemoradiotherapy

Head and Neck Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer (TNBC)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Thyroid Neoplasms

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Medullary Thyroid Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Liver Dysfunction

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.

MGMT-Unmethylated Glioblastoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
Xijing Hospital

Not yet recruiting

An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC

Gastric Cancer

China
Shandong Cancer Hospital and Institute

Terminated

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Endometrial Carcinoma

China
Jinming Yu

Recruiting

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Limited Stage Small Cell Lung Cancer | Not Progressed After First-line Chemoradiotherapy

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Advanced Squamous Non-Small Cell Lung Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital

Unknown

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking Union Medical College Hospital

Recruiting

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

Paraganglioma, Extra-Adrenal | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma | Pheochromocytoma, Metastatic | Paraganglioma, Malignant

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Non-small Cell Lung Cancer

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
First Hospital of Shijiazhuang City

Unknown

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma | Small Cell Lung Cancer | Lung Neoplasm

China
Hubei Cancer Hospital

Recruiting

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Colorectal Cancer

China
First People's Hospital of Hangzhou
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma

Recurrent High-grade Glioma

China
Peng Yuan

Completed

Anlotinib in Metastatic HER2 Negative Breast Cancer

Breast Neoplasm | Antineoplastic Agents | Anlotinib

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Advanced Hepatocellular Carcinoma

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke (EMPHASIS)

Ischemic Stroke, Acute

China
Guangdong Association of Clinical Trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI

NSCLC

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Georgetown University

Unknown

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib)

Parkinson Disease | Parkinsons Disease With Dementia

United States
Zhejiang University
Huashan Hospital; West China Hospital; The First Affiliated Hospital of Zhengzhou... and other collaborators

Terminated

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Hepatocellular Carcinoma

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
Yizhuo Zhang

Unknown

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

Sarcoma
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma

Anlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound Complications

China
The First Hospital of Jilin University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC

Non-Small Cell Lung Cancer

China
LanZhou University
General Hospital of Ningxia Medical University

Unknown

Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy (ALTER-L006)

Advanced Non-squamous NSCLC
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Yonggao Mou
The First Affiliated Hospital of Nanchang University

Recruiting

Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

Glioblastoma

China
Shanghai Zhongshan Hospital

Withdrawn

Adjuvant Therapy With Anlotinib for HCC

Hepatocellular Carcinoma

China
Beijing Union Pharmaceutical Factory Ltd
R&G Pharma Studies Co.,Ltd.

Recruiting

Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD (BGFN-2022-02)

Generalized Anxiety Disorder

China
Changzhou Cancer Hospital of Soochow University

Unknown

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

China

3

Subscribe